Glenmark Life Sciences IPO - KRChoksey's Investment Rationale
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research's IPO Report
Glenmark Life Sciences Ltd. is a leading developer and manufacturer of select high value, non-commoditised active pharmaceutical ingredients in chronic and other therapeutic areas, besides also providing contract development and manufacturing operations services to multinational and specialty pharmaceuticals.
It makes niche and technologically complex molecules requiring research and development driven strong manufacturing capabilities.
Glenmark Life Sciences products have usage in various therapeutic areas including cardiovascular, central nervous system, pain management, diabetes, gastrointestinal disorders and anti-infectives, helping it achieve high market share in select APIs.
The company has posted robust financials over last three years and has a strong management team in place to capture future growth potential.
Click on the attachment to read the full IPO report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.